Results 171 to 180 of about 5,866 (194)

Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim

Journal of Medical Economics, 2020
Ali McBride, Weijia Wang, Karen M Macdonald   +2 more
exaly  

PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia

Cancer Letters, 2016
Ha-Reum Lee, Myung-Hwan Kim, Jae Wha Kim
exaly  

Pegfilgrastim

Reactions Weekly, 2021
openaire   +1 more source

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

Journal of Medical Economics, 2020
Karen M Macdonald, Ali McBride, Neda Alrawashdh   +2 more
exaly  

Thoracic aortitis and aortic dissection following pegfilgrastim administration

European Journal of Cardio-thoracic Surgery, 2017
Yuki Sato
exaly  

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

Supportive Care in Cancer, 2015
Norikazu Masuda
exaly  

A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim

Biologicals, 2017
Nirmesh Shah
exaly  

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

Supportive Care in Cancer, 2015
Derek Weycker, Xiaoyan Li, May Hagiwara
exaly  

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

Annals of Oncology, 2011
exaly  

Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support

Annals of Oncology, 2010
Armando Santoro
exaly